Head-to-head · Value Score
Alan Meds vs Corsica Health
Two GLP-1 deals, scored on the same six factors. Alan Meds lands a Value Score of 90, Corsica Health a 68. Here's who gives you the honest lower price — and where each one bites back.
Alan Meds
#7 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameCorsica Health
#273 · Grade C · Watch List
Est. first month
From $199/mo (3-month plan, compounded)
Save ~85% vs brand-nameThe verdict
Alan Meds takes it on Value Score, 90 to 68 — an est. $99/mo first month, with no teaser step-up baked in. Corsica Health isn't out of it: Shoppers who want side-by-side compounded and brand-name GLP-1 pricing on one platform.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Alan Meds | Corsica Health |
|---|---|---|
| Value Score | 90 (A) | 68 (C) |
| Est. first month | $99/mo | From $199/mo (3-month plan, compounded) |
| Save vs brand-name | ~93% | ~85% |
| Semaglutide | $99/mo | From $199/mo (3-month plan, compounded) |
| Tirzepatide | $145/mo | From $249/mo (3-month plan, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Alan Meds
Double-digit semaglutide ($99) and a $145 tirzepatide, both nationwide, with an oral route for the needle-shy.
Why it's a deal
- $99 flat semaglutide and a low $145 tirzepatide
- Available in all 50 states
- Offers an oral/sublingual route
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Newer operator with a thin public track record
Corsica Health
Corsica Health is a telehealth platform offering both compounded GLP-1s and brand-name FDA-approved injections through a structured assessment, provider review, and medication flow.
Why it's a deal
- Public pricing shown for both compounded and brand-name options — a real transparency advantage
- $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
- LegitScript Certified
- Clear 3-step intake: Assessment, Provider Review, Receive Medication
- $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced
The fine print
- Legal entity name and state of incorporation not disclosed on the site
- Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
- Per-state availability not listed publicly
- First-month promotional pricing not disclosed
- Lab-work inclusion not clearly disclosed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Alan Meds is ranked on the Alan Meds alternatives board, and the same list for the other side is on alternatives to Corsica Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.